Resverlogix Corp. (RVX)

0.300
0.000(0.00%)
  • Volume:
    3,320
  • Bid/Ask:
    0.290/0.300
  • Day's Range:
    0.300 - 0.315
  • Type:Equity
  • Market:Canada
  • ISIN:CA76128M1086
  • CUSIP:76128M108

RVX Overview

Prev. Close
0.3
Day's Range
0.3-0.315
Revenue
-
Open
0.315
52 wk Range
0.29-0.95
EPS
-0.14
Volume
3,320
Market Cap
72.21M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
48,382
P/E Ratio
-
Beta
0.39
1-Year Change
-66.67%
Shares Outstanding
249,014,928
Next Earnings Date
Jun 29, 2022
What is your sentiment on Resverlogix Corp.?
or
Market is currently closed. Voting is open during market hours.

Resverlogix Corp. News

Resverlogix Corp. Analysis

Resverlogix Corp. Company Profile

Resverlogix Corp. Company Profile

Employees
0
Market
Canada

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Very Strong in Epigenetic drug development, believe very close to definitive results on phase 3 mace trial (RVX-208). All signs IMO are pointing to very positive outcome this year. . Yes  I do have shares!
    1